Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials

Expert Opinion on Investigational Drugs · Published 2025-08-25 · DOI 10.1080/13543784.2025.2552846

Authors being retrieved — see the publisher record. https://doi.org/10.1080/13543784.2025.2552846

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Novel Therapeutic Approaches and Alternatives to Antibiotic Therapy for Drug-Resistant Intra-Abdominal Infections · Antibiotics · 2026 · Cites or is cited by this article
Advancements in longevity pharmacology research – are we finally seeing clinical progression? · Expert Opinion on Investigational Drugs · 2026 · Same journal
Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · Expert Opinion on Investigational Drugs · 2025 · Same journal
Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · Expert Opinion on Investigational Drugs · 2026 · Same journal
Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · Expert Opinion on Investigational Drugs · 2026 · Same journal
Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
Menin inhibitors for adult acute myeloid leukemia: 2025 update · Expert Opinion on Investigational Drugs · 2025 · Same journal
Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · Expert Opinion on Investigational Drugs · 2026 · Same journal
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · Expert Opinion on Investigational Drugs · 2026 · Same journal